[{"id":"70012bdf-9a68-4791-98f7-f3a645c2ba06","acronym":"","url":"https://clinicaltrials.gov/study/NCT04295759","created_at":"2021-01-18T20:50:32.592Z","updated_at":"2025-02-25T14:01:55.137Z","phase":"Phase 1","brief_title":"INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas","source_id_and_acronym":"NCT04295759","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" HER-2 • CD4 • ADAM10","pipe":"","alterations":" ","tags":["HER-2 • CD4 • ADAM10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aderbasib (INCB7839)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 07/27/2020","start_date":" 07/27/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2025-02-19"},{"id":"c0529000-1eea-42c3-9cae-d983a7189b6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05943795","created_at":"2023-07-13T18:10:45.267Z","updated_at":"2025-02-25T15:36:23.229Z","phase":"Phase 3","brief_title":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","source_id_and_acronym":"NCT05943795","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 584","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-11"},{"id":"af4c7cda-c517-4da6-b8c2-a10bb4a3610e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04100694","created_at":"2021-01-18T20:03:38.689Z","updated_at":"2025-02-25T16:44:42.630Z","phase":"","brief_title":"Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor","source_id_and_acronym":"NCT04100694","lead_sponsor":"Merus N.V.","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bizengri (zenocutuzumab-zbco)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-05"},{"id":"021a5f18-f5e7-498d-a188-e4903f2c76f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588609","created_at":"2022-10-20T14:11:50.019Z","updated_at":"2025-02-25T16:54:29.545Z","phase":"Phase 2","brief_title":"Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers","source_id_and_acronym":"NCT05588609","lead_sponsor":"Merus N.V.","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • Xtandi (enzalutamide) • abiraterone acetate • Bizengri (zenocutuzumab-zbco)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-02-04"},{"id":"9af50d59-4329-43d7-9f47-4b35e0e157f1","acronym":"eNRGy","url":"https://clinicaltrials.gov/study/NCT02912949","created_at":"2021-01-18T14:18:00.437Z","updated_at":"2025-02-25T16:59:16.918Z","phase":"Phase 2","brief_title":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","source_id_and_acronym":"NCT02912949 - eNRGy","lead_sponsor":"Merus N.V.","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bizengri (zenocutuzumab-zbco)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-03"},{"id":"e5534d1f-e396-45b7-a321-925588805b53","acronym":"","url":"https://clinicaltrials.gov/study/NCT05668858","created_at":"2022-12-30T14:58:33.263Z","updated_at":"2024-07-02T16:35:11.326Z","phase":"Phase 1/2","brief_title":"Clinical Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT05668858","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • izalontamab (SI-B001) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/10/2023","start_date":" 02/10/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-04"},{"id":"258dd981-3155-4a65-b439-66d48123d14a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05020457","created_at":"2021-08-25T14:53:14.347Z","updated_at":"2024-07-02T16:35:21.410Z","phase":"Phase 2","brief_title":"SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.","source_id_and_acronym":"NCT05020457","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • paclitaxel • docetaxel • pemetrexed • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-01-31"},{"id":"7c08cf87-45ad-4ad1-a2a0-cd9cc9ee571c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05203601","created_at":"2023-12-27T20:17:30.683Z","updated_at":"2024-07-02T16:35:25.088Z","phase":"Phase 1","brief_title":"A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.","source_id_and_acronym":"NCT05203601","lead_sponsor":"Shanghai Institute Of Biological Products","biomarkers":" EGFR • HER-2 • TP53 • PIK3CA • ERBB3 • NOTCH1 • NRG1 • NOTCH2 • FAT1 • NOTCH4","pipe":" | ","alterations":" HER-2 overexpression","tags":["EGFR • HER-2 • TP53 • PIK3CA • ERBB3 • NOTCH1 • NRG1 • NOTCH2 • FAT1 • NOTCH4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 11/26/2020","start_date":" 11/26/2020","primary_txt":" Primary completion: 12/06/2022","primary_completion_date":" 12/06/2022","study_txt":" Completion: 12/06/2022","study_completion_date":" 12/06/2022","last_update_posted":"2023-12-27"},{"id":"11e80090-69af-4a10-8567-99e826b98c88","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949606","created_at":"2023-07-20T15:09:17.002Z","updated_at":"2024-07-02T16:35:27.645Z","phase":"Phase 1/2","brief_title":"A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05949606","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • KRAS • BRAF • ALK • MET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • MET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab (SI-B001) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-11-29"},{"id":"4a5c5303-d2d6-439b-bd1d-a7d077defa4f","acronym":"CRESTONE","url":"https://clinicaltrials.gov/study/NCT04383210","created_at":"2021-01-17T17:39:01.678Z","updated_at":"2024-07-02T16:35:40.595Z","phase":"Phase 2","brief_title":"Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors","source_id_and_acronym":"NCT04383210 - CRESTONE","lead_sponsor":"Elevation Oncology","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e seribantumab (MM-121)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 09/29/2020","start_date":" 09/29/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-08-08"},{"id":"a3752eca-3e48-4365-9dba-5171db569837","acronym":"","url":"https://clinicaltrials.gov/study/NCT02167854","created_at":"2021-01-18T10:05:49.948Z","updated_at":"2025-02-25T15:41:41.438Z","phase":"Phase 1","brief_title":"Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer","source_id_and_acronym":"NCT02167854","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HER-2 amplification • PIK3CA mutation","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Piqray (alpelisib) • elgemtumab (LJM-716)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 06/16/2014","start_date":" 06/16/2014","primary_txt":" Primary completion: 07/07/2021","primary_completion_date":" 07/07/2021","study_txt":" Completion: 07/07/2021","study_completion_date":" 07/07/2021","last_update_posted":"2021-07-09"},{"id":"428f1c7d-3c9d-4ad6-9649-3c2232730cb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01211483","created_at":"2021-06-17T00:52:36.913Z","updated_at":"2024-07-02T16:36:29.003Z","phase":"Phase 1b/2","brief_title":"Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01211483","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" KEAP1 • NRG1","pipe":"","alterations":" ","tags":["KEAP1 • NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • patritumab (U3-1287)"],"overall_status":"Completed","enrollment":" Enrollment 222","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 10/01/2013","primary_completion_date":" 10/01/2013","study_txt":" Completion: 11/23/2013","study_completion_date":" 11/23/2013","last_update_posted":"2021-06-16"},{"id":"25c037e9-0c80-4006-a0eb-eacdbbe10f13","acronym":"","url":"https://clinicaltrials.gov/study/NCT01598077","created_at":"2021-01-18T06:49:57.264Z","updated_at":"2024-07-02T16:36:37.158Z","phase":"Phase 1","brief_title":"A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer","source_id_and_acronym":"NCT01598077","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elgemtumab (LJM-716)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2020-12-19"},{"id":"221ab4a7-e8a1-42f3-affc-34130424c231","acronym":"","url":"https://clinicaltrials.gov/study/NCT01911936","created_at":"2021-01-18T08:37:10.777Z","updated_at":"2024-07-02T16:36:37.216Z","phase":"Phase 1","brief_title":"A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01911936","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elgemtumab (LJM-716)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 03/01/2015","primary_completion_date":" 03/01/2015","study_txt":" Completion: 03/01/2015","study_completion_date":" 03/01/2015","last_update_posted":"2020-12-17"},{"id":"5f8ce650-2a00-4f62-8957-6ea4665a0d6f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02473731","created_at":"2021-01-18T11:54:36.133Z","updated_at":"2024-07-02T16:36:57.461Z","phase":"Phase 1","brief_title":"A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients","source_id_and_acronym":"NCT02473731","lead_sponsor":"Celldex Therapeutics","biomarkers":" ERBB3","pipe":"","alterations":" ","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-3379"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 09/22/2016","primary_completion_date":" 09/22/2016","study_txt":" Completion: 10/10/2016","study_completion_date":" 10/10/2016","last_update_posted":"2019-08-01"},{"id":"aec8c31d-7488-4935-b5b7-dd30f1b33a68","acronym":"","url":"https://clinicaltrials.gov/study/NCT01966445","created_at":"2021-01-18T08:56:18.757Z","updated_at":"2024-07-02T16:36:58.502Z","phase":"Phase 1","brief_title":"Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors","source_id_and_acronym":"NCT01966445","lead_sponsor":"GlaxoSmithKline","biomarkers":" ERBB3 • CA 19-9","pipe":"","alterations":" ","tags":["ERBB3 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2849330"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 11/26/2013","start_date":" 11/26/2013","primary_txt":" Primary completion: 09/18/2017","primary_completion_date":" 09/18/2017","study_txt":" Completion: 09/18/2017","study_completion_date":" 09/18/2017","last_update_posted":"2019-07-01"},{"id":"e87aedf6-d57c-48bd-b9d5-e959819f1c59","acronym":"","url":"https://clinicaltrials.gov/study/NCT02345174","created_at":"2021-01-18T11:09:08.618Z","updated_at":"2024-07-02T16:37:02.615Z","phase":"Phase 1","brief_title":"Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors","source_id_and_acronym":"NCT02345174","lead_sponsor":"GlaxoSmithKline","biomarkers":" ERBB3","pipe":" | ","alterations":" ERBB3 expression","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERBB3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2849330"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 03/19/2015","start_date":" 03/19/2015","primary_txt":" Primary completion: 06/02/2016","primary_completion_date":" 06/02/2016","study_txt":" Completion: 06/02/2016","study_completion_date":" 06/02/2016","last_update_posted":"2019-02-21"},{"id":"0d8d95d1-e811-40d1-bfc3-cea16cccfecf","acronym":"CARRIE","url":"https://clinicaltrials.gov/study/NCT02399137","created_at":"2021-01-18T11:26:45.591Z","updated_at":"2024-07-02T16:37:06.821Z","phase":"Phase 2","brief_title":"A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02399137 - CARRIE","lead_sponsor":"Merrimack Pharmaceuticals","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • istiratumab (MM-141)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 08/01/2018","study_completion_date":" 08/01/2018","last_update_posted":"2018-09-18"},{"id":"2cc8d9fa-6ae0-4cb9-951e-51c44223d3b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00820560","created_at":"2021-01-18T03:07:09.830Z","updated_at":"2024-07-02T16:37:14.752Z","phase":"Phase 1","brief_title":"Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors","source_id_and_acronym":"NCT00820560","lead_sponsor":"Incyte Corporation","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aderbasib (INCB7839)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 01/01/2005","start_date":" 01/01/2005","primary_txt":" Primary completion: 01/01/2009","primary_completion_date":" 01/01/2009","study_txt":" Completion: 01/01/2009","study_completion_date":" 01/01/2009","last_update_posted":"2018-01-17"},{"id":"1d10a79c-1aeb-47d8-b359-538633c036e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01918254","created_at":"2021-01-18T08:39:09.173Z","updated_at":"2025-02-25T14:00:14.403Z","phase":"Phase 1","brief_title":"A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein","source_id_and_acronym":"NCT01918254","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ERBB3","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2 • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Perjeta (pertuzumab) • lumretuzumab (RG7116)"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 08/06/2013","start_date":" 08/06/2013","primary_txt":" Primary completion: 10/07/2016","primary_completion_date":" 10/07/2016","study_txt":" Completion: 10/07/2016","study_completion_date":" 10/07/2016","last_update_posted":"2017-09-12"},{"id":"2c3f46c2-6b83-4807-b2db-f86cdef891e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02014909","created_at":"2021-01-18T09:12:56.219Z","updated_at":"2024-07-02T16:37:19.624Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors","source_id_and_acronym":"NCT02014909","lead_sponsor":"Celldex Therapeutics","biomarkers":" EGFR • HER-2 • KRAS • BRAF","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • BRAF V600 • EGFR expression • EGFR wild-type • RAS wild-type","tags":["EGFR • HER-2 • KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • BRAF V600 • EGFR expression • EGFR wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-3379"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 05/25/2017","primary_completion_date":" 05/25/2017","study_txt":" Completion: 06/05/2017","study_completion_date":" 06/05/2017","last_update_posted":"2017-07-24"},{"id":"39b75b55-ad92-4eb5-b91c-32fcb9289773","acronym":"","url":"https://clinicaltrials.gov/study/NCT01482377","created_at":"2021-01-18T06:11:26.844Z","updated_at":"2024-07-02T16:37:26.198Z","phase":"Phase 1a/1b","brief_title":"A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin","source_id_and_acronym":"NCT01482377","lead_sponsor":"Hoffmann-La Roche","biomarkers":" EGFR • ERBB3","pipe":" | ","alterations":" EGFR expression • ERBB3 expression • EGFR positive","tags":["EGFR • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • ERBB3 expression • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • erlotinib • lumretuzumab (RG7116)"],"overall_status":"Completed","enrollment":" Enrollment 145","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2017-01-27"},{"id":"51056652-9a0d-45f8-9b5a-cae8c8df42a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01652482","created_at":"2021-01-18T07:07:15.418Z","updated_at":"2024-07-02T16:37:27.874Z","phase":"Phase 2","brief_title":"Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)","source_id_and_acronym":"NCT01652482","lead_sponsor":"Genentech, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium • duligotuzumab (MEHD7945A)"],"overall_status":"Completed","enrollment":" Enrollment 135","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":" Completion: 11/01/2014","study_completion_date":" 11/01/2014","last_update_posted":"2016-11-02"},{"id":"6f8d44f4-9674-43e8-8558-1e0785beeed1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01209195","created_at":"2021-01-18T04:51:07.539Z","updated_at":"2024-07-02T16:37:29.278Z","phase":"Phase 1","brief_title":"A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers","source_id_and_acronym":"NCT01209195","lead_sponsor":"Merrimack Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • seribantumab (MM-121)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 05/01/2014","primary_completion_date":" 05/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2016-09-08"}]